Phase II Evaluation of Amonafide in Advanced Sarcoma: A Southwest Oncology Group Study |
| |
| Authors: | Saundra S. Buys Barbara Metch Stanley P. Balcerzak John R. Neefe W. J. Stuckey |
| |
| Affiliation: | a University of Utah Medical Center, Salt Lake City, Utahb Southwest Oncology Group Statistical Center, Seattle, Washingtonc Ohio State University Health Center, Columbus, Ohiod University of Kentucky Medical Center, Lexington, Kentuckye Tulane University Medical Center, New Orleans, Louisiana |
| |
| Abstract: | Soft tissue sarcomas are generally resistant to most chemotherapeutic agents, and individuals with advanced disease have a poor prognosis. We evaluated amonafide, a new drug that has significant activity against several tumor cell lines, to determine its activity against sarcomas. Amonafide was administered to 18 patients with advanced soft tissue sarcoma (16 of whom had received prior chemotherapy) at a dose of 300 mg/m2 over 60 min daily for 5 days. Courses were repeated every 21 days. Toxicity was mild, but no responses were observed. We conclude that amonafide is not an active agent in previously treated, advanced soft tissue sarcomas in the dose and schedule utilized. |
| |
| Keywords: | |
| 本文献已被 InformaWorld 等数据库收录！ |
|
